Biotech Values

[DewDiligence]

I actually consider this and MNTA’s recent hiring spree as somewhat bullish. [Craig Wheeler] and co have historically been very conservative when it comes to using cash. My reading is they anticipate M-copax approval before the patent date and they also expect the drug to be rather profitable as well (including significant time as the only generic entrant).

Opinion noted. The new executive position just strikes me as premature if it truly involves looking beyond the BAX collaboration toward additional business development opportunities within the FoB arena.